Collegium Pharmaceutical Inc. (COLL)
NASDAQ:COLL
Want to see COLL full AI Analyst Report?
COLL Stock Chart & Stats
$34.41
$3.70(12.70%)
At close: 4:00 PM EST
$34.41
$3.70(12.70%)
Day’s Range― - ―
52-Week Range$29.11 - $50.79
Previous CloseN/A
Volume233.62K
Average Volume (3M)432.17K
Market Cap
$1.12B
Enterprise Value$1.63B
Total Cash (Recent Filing)$421.75M
Total Debt (Recent Filing)$808.06M
Price to Earnings (P/E)14.8
Beta0.47
Next Earnings
Jul 30, 2026EPS Estimate
1.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.37
Shares Outstanding32,433,780
10 Day Avg. Volume413,375
30 Day Avg. Volume432,173
Financial Highlights & Ratios
PEG Ratio-3.12
Price to Book (P/B)4.87
Price to Sales (P/S)1.88
P/FCF Ratio4.48
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit3.37
Enterprise Value/Ebitda2.67
Forecast
1Y Price Target
$53.40Price Target Upside55.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)7.66
Revenue Forecast (FY)$872.42M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationVery strong trailing free cash flow (~$330M) and significant FCF growth provide durable internal funding for debt paydown, M&A financing, reinvestment in commercial programs, and shareholder returns without reliance on dilutive equity, bolstering long-term financial resilience.
High And Sustainable MarginsRobust gross (~61%) and EBIT (~30%) margins reflect branded specialty product economics and pricing power. These margins create durable operating leverage that funds commercial investment, supports profitability through pricing or mix shifts, and cushions reimbursement or cost pressures over time.
AZSTARYS Acquisition Extends Patent-protected ADHD FranchiseBuying AZSTARYS immediately broadens ADHD portfolio, adds near-term revenue and EBITDA accretion, and secures a patent-protected asset through 2037. The deal materially diversifies revenue mix and, if synergies are realized, strengthens medium-term growth and competitive position in neuropsychiatry.
Bears Say
Elevated LeverageMaterial absolute debt and a debt-to-equity ratio near 2.6 constrain strategic flexibility and increase refinancing and interest-rate exposure. While cash generation is strong, leverage magnifies downside risk and leaves less cushion for adverse commercial or regulatory shocks.
Generic/authorized Generic Risk To NucyntaAuthorized generic entry structurally pressures branded volumes and net pricing for Nucynta. Profit-share mechanics provide partial offset, but long-term erosion of franchise revenue and margin is likely unless growth from other brands or new launches fully offsets loss of branded market share.
Rising Commercial Costs And Limited Near-term Margin ExpansionManagement's strategy to grow ADHD through a larger sales force and marketing raises recurring operating expenses. With only modest near-term adjusted EBITDA growth guided, elevated commercial spend could compress margin expansion and slow operating-leverage benefits until revenue gains and synergies materialize.
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical Inc.’s price range in the past 12 months?
Collegium Pharmaceutical Inc. lowest stock price was $29.11 and its highest was $50.79 in the past 12 months.
What is Collegium Pharmaceutical Inc.’s market cap?
Collegium Pharmaceutical Inc.’s market cap is $1.12B.
When is Collegium Pharmaceutical Inc.’s upcoming earnings report date?
Collegium Pharmaceutical Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were Collegium Pharmaceutical Inc.’s earnings last quarter?
Collegium Pharmaceutical Inc. released its earnings results on May 07, 2026. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.524 by $0.236.
Is Collegium Pharmaceutical Inc. overvalued?
According to Wall Street analysts Collegium Pharmaceutical Inc.’s price is currently Undervalued.
Does Collegium Pharmaceutical Inc. pay dividends?
Collegium Pharmaceutical Inc. does not currently pay dividends.
What is Collegium Pharmaceutical Inc.’s EPS estimate?
Collegium Pharmaceutical Inc.’s EPS estimate is 1.72.
How many shares outstanding does Collegium Pharmaceutical Inc. have?
Collegium Pharmaceutical Inc. has 32,433,780 shares outstanding.
What happened to Collegium Pharmaceutical Inc.’s price movement after its last earnings report?
Collegium Pharmaceutical Inc. reported an EPS of $1.76 in its last earnings report, beating expectations of $1.524. Following the earnings report the stock price went up 7.724%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in COLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.40 (55.19% Upside)
$53.40 (55.19% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 81.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $628.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.02%
12-Months-Change
Fundamentals
Return on Equity
26.74%
Trailing 12-Months
Asset Growth
1.26%
Trailing 12-Months
Company Description
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
COLL Company Deck
COLL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple clear commercial and financial positives: robust JORNAY prescription and revenue momentum, a durable pain portfolio, strong cash generation, and a strategic, accretive acquisition (AZSTARYS) that extends portfolio longevity and is expected to add revenue and synergies. Noted headwinds include higher operating expenses from deliberate commercial investments, generic/authorized generic dynamics for Nucynta, seasonal script pressure, and a temporary increase in leverage to fund the acquisition. Overall the company presented growth initiatives with supporting data and a plan to manage risks, and management reaffirmed guidance while outlining accretion and synergies from AZSTARYS.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$53.40
▲(55.19% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Ownership Overview
12.73% Insiders
32.75% Mutual Funds
16.59% Other Institutional Investors
9.21% Public Companies and
Individual Investors